Biogen Idec Inc (BIIB): Today's Featured Health Care Loser

Biogen Idec ( BIIB) pushed the Health Care sector lower today making it today's featured Health Care loser. The sector as a whole closed the day up 0.2%. By the end of trading, Biogen Idec fell $1.51 (-1%) to $144.12 on light volume. Throughout the day, 736,030 shares of Biogen Idec exchanged hands as compared to its average daily volume of 1.3 million shares. The stock ranged in price between $143.98-$145.41 after having opened the day at $144.72 as compared to the previous trading day's close of $145.63. Other company's within the Health Care sector that declined today were: Sunshine Heart ( SSH), down 16.4%, Natural Alternatives International ( NAII), down 15%, Cardiome Pharma Corporation ( CRME), down 13.2%, and CombiMatrix Corporation ( CBMX), down 11.4%.

Biogen Idec Inc. discovers, develops, manufactures, and markets therapies for the treatment of neurodegenerative diseases, hemophilia, and autoimmune disorders in the United States and internationally. Biogen Idec has a market cap of $34.89 billion and is part of the drugs industry. The company has a P/E ratio of 28.6, equal to the average drugs industry P/E ratio and above the S&P 500 P/E ratio of 17.7. Shares are up 32.3% year to date as of the close of trading on Tuesday. Currently there are 13 analysts that rate Biogen Idec a buy, no analysts rate it a sell, and six rate it a hold.

TheStreet Ratings rates Biogen Idec as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, reasonable valuation levels and solid stock price performance. We feel these strengths outweigh the fact that the company shows weak operating cash flow.

On the positive front, Medgenics ( MDGN), up 43%, Rexahn Pharmaceuticals ( RNN), up 29.5%, EntreMed ( ENMD), up 24%, and Coronado Biosciences ( CNDO), up 20%, were all gainers within the health care sector with Human Genome ( HGSI) being today's featured health care sector winner.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).
null

If you liked this article you might like

Illumina Lights the Way for Biotechs

Illumina Lights the Way for Biotechs

European Pharma Companies Slip on MS Pricing Probe

Biogen Stock Climbs After Goldman Adds to its 'Conviction Buy' List

Pfizer's Poor Earnings Feed the Allergan Tie-Up Fire